Rethymic Implant
Product Images NDC 72359-001

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rethymic (NDC 72359-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sumitomo Pharma America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rethymic 01)

An instructional illustration showing the preparation of RETHYMIC implant tissue. It depicts tissue segments being transferred from one petri dish to another, and then tissue being cut or trimmed before final placement in a petri dish, indicating steps in preparing the allogenic thymocyte-depleted thymus tissue implant for intramuscular administration.*

FDA Label Image

Figure 2 (Rethymic 02)

An anatomical illustration showing a leg with an incision site indicated by dashed lines and an arrow pointing to a cross-sectional view of an open muscle compartment, depicting the muscle fibers and surrounding connective tissue layers separated by arrows. This diagram seems to represent a surgical or procedural approach related to intramuscular implantation.*

FDA Label Image

Figure 3 (Rethymic 03)

An instructional diagram showing the use of forceps to handle or implant a piece of tissue into muscle, depicting a surgical technique related to the intramuscular implant of a thymus tissue product.*

FDA Label Image

Figure 4 (Rethymic 04)

An illustration showing an intramuscular implant identified as allogenic thymocyte-depleted thymus tissue, approximately 1 cm in size, consistent with the RETHYMIC 22000 mm/1 implant by Sumitomo Pharma America, Inc. The diagram depicts tissue structure with an outlined scale bar for measurement.*

FDA Label Image

Figure 5 (Rethymic 05)

Kaplan-Meier survival curve comparing the RETHYMIC clinical trial population (N=95) with a natural history population (N=49) over time in years. The graph shows survival estimates with censored data points for the clinical trial group and lower survival in the natural history group. A table below the graph shows the number of patients at risk and events over time for both populations.*

FDA Label Image

Principal Display Panel (11 Container Box)

Label for RETHYMIC allogenic processed thymus tissue-agdc implant. It shows dosage for an entire lot ranges from 5,000 to 22,000 mm², with the entire lot containing 22,000 mm² of thymus tissue. The product is preservative free and formulated with fetal bovine serum. Storage instructions indicate storage at room temperature without freezing or refrigeration. The label includes lot number GMP-336 and expiration date of August 17, 2021. Manufactured for Enzyvant Therapeutics Inc., Cambridge, MA, with a contact telephone number provided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.